CL2017000191A1 - Método - Google Patents
MétodoInfo
- Publication number
- CL2017000191A1 CL2017000191A1 CL2017000191A CL2017000191A CL2017000191A1 CL 2017000191 A1 CL2017000191 A1 CL 2017000191A1 CL 2017000191 A CL2017000191 A CL 2017000191A CL 2017000191 A CL2017000191 A CL 2017000191A CL 2017000191 A1 CL2017000191 A1 CL 2017000191A1
- Authority
- CL
- Chile
- Prior art keywords
- subject
- agent
- administrating
- union
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
<p>LA INVENCIÓN SE REFIERE A UN MÉTODO PARA MEJORAR EL BENEFICIO DE UNA TERAPIA O UN AGENTE TERAPÉUTICO PARA UN SUJETO. EL MÉTODO COMPRENDE (A) ADMINISTRAR AL SUJETO UN AGENTE QUE REDUCE LIA UNIÓN AL RECEPTOR Fc DE MOLÉCULAS DE IgG EN SUERO EN EL SUJETO; Y ADMINISTRAR POSTERIORMENTE DICHA TERAPIA O DICHO AGENTE TERAPÉUTICO AL SUJETO. LA INVENCIÓN SE REFIERE TAMBIÉN A UN MÉTODO PARA REDUCIR EL EFECTO DE AUTOANTICUERPOS PATÓGENOS EN UN SUJETO, COMPRENDIENDO EL MÉTODO (A) ADMINISTRAR AL SUJETO UN AGENTE QUE REDUCE LA UNIÓN AL RECEPTOR DE Fc DE MOLÉCULAS DE IgG EN SUERO EN EL SUJETO Y OPCIONALMENTE (B) SOMETER SUBSECUENTEMENTE AL SUJETO A UN TRATAMIENTO QUE ELIMINA AUTOANTICUERPOS ENDÓGENOS. LA INVENCIÓN SE REFIERE TAMBIÉN A UN KIT PARA LLEVAR A CABO UN MÉTODO DE LA INVENCIÓN.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1413240.1A GB201413240D0 (en) | 2014-07-25 | 2014-07-25 | Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000191A1 true CL2017000191A1 (es) | 2017-08-25 |
Family
ID=51587261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000191A CL2017000191A1 (es) | 2014-07-25 | 2017-01-25 | Método |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10973889B2 (es) |
| EP (2) | EP3171891B1 (es) |
| JP (1) | JP6708641B2 (es) |
| KR (2) | KR20230119267A (es) |
| CN (2) | CN106714834A (es) |
| AU (1) | AU2015294125B2 (es) |
| BR (1) | BR112017001420A2 (es) |
| CA (1) | CA2955704A1 (es) |
| CL (1) | CL2017000191A1 (es) |
| CO (1) | CO2017000571A2 (es) |
| DK (1) | DK3171891T3 (es) |
| EA (1) | EA039169B1 (es) |
| ES (1) | ES3054696T3 (es) |
| FI (1) | FI3171891T3 (es) |
| GB (1) | GB201413240D0 (es) |
| HR (1) | HRP20251560T1 (es) |
| IL (1) | IL249981B (es) |
| LT (1) | LT3171891T (es) |
| MX (1) | MX2017001138A (es) |
| MY (1) | MY196858A (es) |
| PL (1) | PL3171891T3 (es) |
| PT (1) | PT3171891T (es) |
| RS (1) | RS67520B1 (es) |
| SG (1) | SG11201700172WA (es) |
| SI (1) | SI3171891T1 (es) |
| WO (1) | WO2016012285A2 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| WO2017210360A1 (en) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| CA3149395A1 (en) * | 2019-08-01 | 2021-02-04 | Memorial Sloan-Kettering Cancer Center | Cells for improved immunotherapy and uses thereof |
| EP4096691A1 (en) | 2020-01-28 | 2022-12-07 | Freeline Therapeutics Limited | Improved assay for determining neutralising antibody titre to a viral vektor |
| GB202002072D0 (en) * | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| GB202003129D0 (en) * | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN120078887A (zh) * | 2020-09-21 | 2025-06-03 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| EP4433587A2 (en) | 2021-11-15 | 2024-09-25 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| IL315305A (en) | 2022-03-17 | 2024-10-01 | Astrazeneca Ireland Ltd | Improved IgG-degrading enzymes and methods of using them |
| AU2023383441A1 (en) | 2022-11-18 | 2025-06-05 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| CN116087528A (zh) * | 2022-12-27 | 2023-05-09 | 华中科技大学同济医学院附属同济医院 | 一种sqtsm1蛋白在卵巢早衰的应用 |
| WO2024148276A1 (en) | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2025047848A1 (ja) | 2023-08-30 | 2025-03-06 | アステラス製薬株式会社 | IdeZ改変体 |
| WO2025248469A1 (en) * | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | TREATMENT OF IgG-RELATED DISEASES |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| GB202413764D0 (en) | 2024-09-18 | 2024-10-30 | Genovis Ab | Immunoglobulin proteases and their uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| JPH0612624B2 (ja) * | 1984-06-20 | 1994-02-16 | 株式会社日立製作所 | 半導体集積回路装置 |
| US6006752A (en) * | 1996-05-09 | 1999-12-28 | The General Hospital Corporation | Mixed chimerism and tolerance |
| CN105770871A (zh) * | 2005-06-09 | 2016-07-20 | 汉莎医药有限公司 | IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途 |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| GB2427360A (en) * | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| CN102584989B (zh) * | 2007-09-14 | 2015-05-13 | 季诺维斯公司 | 用于解离Fcgamma-受体-IgG复合物及纯化与检测IgG的方法和试剂盒 |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) * | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| TWI626491B (zh) * | 2012-12-10 | 2018-06-11 | 布萊恩荷登視覺協會 | 用於視力校正之具有一或多個多正焦區域之眼用光學透鏡 |
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
-
2014
- 2014-07-25 GB GBGB1413240.1A patent/GB201413240D0/en not_active Ceased
-
2015
- 2015-07-10 HR HRP20251560TT patent/HRP20251560T1/hr unknown
- 2015-07-10 IL IL249981A patent/IL249981B/en unknown
- 2015-07-10 DK DK15756845.2T patent/DK3171891T3/da active
- 2015-07-10 CN CN201580049441.3A patent/CN106714834A/zh active Pending
- 2015-07-10 SG SG11201700172WA patent/SG11201700172WA/en unknown
- 2015-07-10 EP EP15756845.2A patent/EP3171891B1/en active Active
- 2015-07-10 MY MYPI2017000280A patent/MY196858A/en unknown
- 2015-07-10 US US15/328,879 patent/US10973889B2/en active Active
- 2015-07-10 CN CN202210234712.4A patent/CN114949187A/zh active Pending
- 2015-07-10 WO PCT/EP2015/065895 patent/WO2016012285A2/en not_active Ceased
- 2015-07-10 PT PT157568452T patent/PT3171891T/pt unknown
- 2015-07-10 PL PL15756845.2T patent/PL3171891T3/pl unknown
- 2015-07-10 EP EP25199052.9A patent/EP4663755A3/en active Pending
- 2015-07-10 MX MX2017001138A patent/MX2017001138A/es unknown
- 2015-07-10 KR KR1020237026683A patent/KR20230119267A/ko not_active Ceased
- 2015-07-10 SI SI201532086T patent/SI3171891T1/sl unknown
- 2015-07-10 FI FIEP15756845.2T patent/FI3171891T3/fi active
- 2015-07-10 KR KR1020177005456A patent/KR102565244B1/ko active Active
- 2015-07-10 EA EA201790192A patent/EA039169B1/ru unknown
- 2015-07-10 BR BR112017001420A patent/BR112017001420A2/pt not_active Application Discontinuation
- 2015-07-10 ES ES15756845T patent/ES3054696T3/es active Active
- 2015-07-10 CA CA2955704A patent/CA2955704A1/en active Pending
- 2015-07-10 AU AU2015294125A patent/AU2015294125B2/en active Active
- 2015-07-10 LT LTEPPCT/EP2015/065895T patent/LT3171891T/lt unknown
- 2015-07-10 JP JP2017524097A patent/JP6708641B2/ja active Active
- 2015-07-10 RS RS20251260A patent/RS67520B1/sr unknown
-
2017
- 2017-01-24 CO CONC2017/0000571A patent/CO2017000571A2/es unknown
- 2017-01-25 CL CL2017000191A patent/CL2017000191A1/es unknown
-
2021
- 2021-03-03 US US17/191,634 patent/US12397044B2/en active Active
-
2025
- 2025-07-07 US US19/261,759 patent/US20260000739A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
| SA519402159B1 (ar) | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها | |
| EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
| GEP20217252B (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| EP4233873A3 (en) | Implantable scaffolds for treatment of sinusitis | |
| PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| EA201692477A1 (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
| CA3010708A1 (en) | Methods of administering hepcidin | |
| AU2017310412A8 (en) | Method of improving connective tissue attachment using anti-sclerostin antibodies | |
| MX2020003563A (es) | Anticuerpo anti-pacap. | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| EA201591513A1 (ru) | Терапевтическое применение антител к vegfr1 (варианты) | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| CR20160369A (es) | Composiciones para uso en el tratamiento de afecciones alérgicas |